Tae-han Kim, CEO of BioLogics will be reappointed

Promotions were carried out on January 30

Sang-jin Kim ,general manager of Samsungbioepis, was promoted to vice president

Tae-han Kim, CEO of Samsung BioLogics will hold his fourth term in March

Samsungbioepis will operate the system of two vice presidents, and Tae-han Kim, CEO of SamsungbioLogics has confirmed that it is four consecutive years.

 

The two companies made such key positions on January 30.

 

The figures reflect results from last year's performance.

 

Sang-Jin Park, Vice President of Samsungbioepis

Seven people were promoted.

 

Another vice president was appointed.

 

Sang-jin Park, 50-year-old general manager, was promoted to vice president.

 

Park is a physician and joined Samsungbioepis in July 2018 after serving as head of the German GSK and representative of AstraZeneca Korea.

 

As a result, Samsungbioepis has two vice presidents.

 

Until Sang-jin Park was appointed, Chang-hoon Choi(60) was Vice President .

 

In addition to Sang-jin Park, Samsungbioepis has appointed Kyung-A Kim, QE (Quality Evaluation) Team Manager, and Young-Pil Lee.

 

PD (Process Development) Team.

 

Hyung-ki Park, CMC Group Head of RA (Regulatory Affairs), Won-young Yoo, Cell Line 1 Group Head of Development Division , Soyoung Lee, Head of SCM Team of Production Division, and Jinhan Jung ,Head of Production Management Group of were promoted.

 

The promotions reflected achievements.

 

Samsungbioepis expects its first profit in eight years.

 

Samsungbioepis posted operating loss of ₩102.7 billion in 2017.

 

The market revenue is expected to reach ₩1 trillion.

 

Samsungbioepis entrusts global distribution to partner companies, and only a certain proportion of ₩ 1 trillion will be captured.

 

Samsungbioepis had sales of ₩368.7 billion in 2018 and last year exceeded it in the third quarter.

 

Tae-han Kim, CEO of Samsung BioLogics

Kim Tae-han, CEO of Samsung Biologics, 63 years old, has virtually confirmed his term.

 

If there is no change in the position of the representative on promotion on January 30, he will be reappointed on March 23.

 

Samsung Biologics announced the promotion on the 30th, including promotion to the executive director of C & C Center, Ho-yeol Yoon.

 

Four executives including Eun-young Yang, head of CDO project team, Se-kang Park, DS2 culture part process manager, Yong-hwan Jin, DS2 MSAT team leader, and Ki-jung Kim, executive director of global customer support team, were appointed as executive directors.

 

There was no change in the position of representative in this performance assessment.

 

Tae-han Kim , CEO of Samsung Biologics, is expected to be re-elected at the general shareholders' meeting on March 23.

 

If he is re-elected, it is his fourth term.

 

In general, Samsung affiliates' promotions are conducted after the presidents' appointments.

 

Resignation of Kim's position as a CEO was a concern.

 

Mr.

 

Kim is the oldest and longest CEO of Samsung Group's listed subsidiaries, and he is at the center of controversy over the issue of fraudulent accounting.

 

Samsung BioLogics posted ₩701.6 billion in sales last year.

 

This is a 30.9% increase from the previous year (₩535.8 billion).

 

Operating profit came in at ₩917.7 billion, up 64.8% from the previous year (₩55.7 billion).